Ring Therapeutics Presents Data on Anellogy Platform at the ESGCT 28th Annual Congress

CAMBRIDGE, Mass., — Ring Therapeutics (“Ring”), a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced preclinical data highlighting its Anellogy™ platform. The data validates the potential to utilize anelloviruses as a new class of gene therapy vectors with potential to address notable industry challenges such as tropism, safety, immunogenicity and redosing. Results were presented at the 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), which took place virtually from October 19-22, 2021.

Title: Anelloviruses are highly diverse, ubiquitous commensal denizens of the human virome, and show promising properties as novel gene delivery vectors
Presenter: Nathan Yozwiak
Presentation Number: P332

The presentation demonstrates that anelloviruses display optimal characteristics for a new viral vector platform. Key highlights from the presentation include:

• Diversity – Anelloviruses are an extremely diverse family of human commensal viruses. This diversity suggests a promising vast pool of targets for vectorization with low human immunogenicity.
• Persistence – Anelloviruses are both highly infective and durable. They are persistent in blood transfusion recipients with donor anelloviruses detected in recipients more than 200 days post transfusion (last data point of collection).
• Redosability – Transfusion studies also suggest anelloviruses are redosable due to significant similarity between strains found in donors and recipients, co-existing without causing pathologic immune responses.
• Synthesis – Anelloviruses can be synthesized using Ring’s proprietary Anellogy platform which facilitated creation of the first in vitro produced human anellovirus.
• Vectorization – Synthesized anelloviruses can be vectorized.
• Low pre-existing immunity – Like native anelloviruses, Anellovector Ring 46 has low pre-existing immunity in humans.

Tuyen Ong, CEO of Ring and CEO-Partner of Flagship Pioneering added, “Anellovectors address key challenges in today’s gene therapies – toxicity, inability to redose, limited tropism, and potential for tumorigenesis. Anellovectors can be engineered to deliver a broad spectrum of therapeutic modalities, all without eliciting a robust immune response that plagues current vectors. Through harnessing the potential of anelloviruses, we hope to drive a new paradigm in gene therapy where the field can potentially safely address a large range of diseases with greater precision and dose adjustability.”